Vaccines and mRNA-based technologies have rapidly emerged as promising new therapeutic modalities, but Indian companies are lagging behind in adopting these innovation platforms.
A report by foreign brokerage Jefferies said that Indian companies are missing the bus on relatively low-risk innovation.
At a recent health conference in the US, several vaccine companies, including CureVac, Valneva, BioNtech and Novavax, set out their growth plans for a post-Covid world.
The report said that mass inoculation with mRNA vaccines has validated the mRNA technology and put vaccines in the spotlight. The companies set out plans to use mRNA technology/vaccines for other infectious diseases, such as flu and Chikungunya, and in oncology.